Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTx-1301 in Children With ADHD
NCT05924594Phase 3Suspended
- Sponsor
- Cingulate Inc.
- Start
- Jul 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CTx-1301 in attention deficit hyperactivity disorder (ADHD), sponsored by Cingulate Inc.. Started Jul 2023; status: suspended.
02
Drugs
CTx-1301
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05924594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924594.